GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-05-19| ChinaFunding

China’s Hengrui Buds Off New Biotech With 11 Therapeutic Programs

by Joy Lin
Share To

Jiangsu Hengrui Pharmaceuticals, a Chinese company, has launched a Luzsana Biotechnology, arming the new subsidiary with 11 therapeutic programs in various stages of development. The two companies will co-develop medicines together, with the aim to sell the products in North America, Europe and Japan. 

Luzsana will share details of its oncology pipeline at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. 

 

Partnership to Access Global R&D Resources

 

From the start, Luzsana, dubbed a “healing light” by Hengrui, will work closely with its parent company to access assets and research and development resources. Luzsana can select from Hengrui’s pipeline of more than 250 clinical studies across multiple therapeutic areas as well as 16 R&D centers with more than 5,400 research staff. The company itself will have locations in Princeton, New Jersey, Basel, Switzerland, and Tokyo, Japan.

Luzsana’s initial pipeline tilts heavily towards oncology, with 8 of 11 products focusing on the area. The company will collaborate with Hengrui to commercialize the candidates, which range from preclinical to Phase 3 assets. 

Scott Filosi, CEO of Luzsana, believes a “healthcare paradox” is at work when it comes to giving medical products to patients who need them. 

“There are more innovative medicines than ever being developed across the globe, yet many people continue to face barriers in terms of availability, accessibility and affordability. For example, while the World Health Organization notes that there are 25 essential cancer medications, only 10% of countries have made all 25 available to patients.”

According to Filosi, the partnership between Luzsana and Hengrui will cut development costs, allowing the companies to invest more in solutions that will increase the availability, accessibility and affordability of medical products. 

 

Hengrui Edges Closer to FDA with Liver Cancer Drug

 

Hengrui recently reported positive Phase 3 data for its combination therapy of rivoceranib and camrelizumab for liver cancer, showing that the two treatments met primary endpoints. 

The company said it expects to begin talks with the US FDA for a potential new drug application, which would bring it closer to a launch in the North American market. 

Camrelizumab is already approved in China under the brand name AiRuiKa across multiple cancer indications. Rivoceranib has also been approved in the country under the brand name Aitan to treat stomach cancer and second-line liver cancer. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
World Cancer Day 2025: “United by Unique” – All About Personalized Care
2025-02-04
IPO
China’s Ascentage Snatches First Biotech IPO Price of 2025, Raking in $126M
2025-01-24
Drug Promotion, Nonprescription Pathways, and Advanced Manufacturing: FDA’s Key Focus Areas in 2024 and What’s Next for 2025
2025-01-23
LATEST
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top